Indeed, by correlating inhibitor sensitivity to oncogenic alterations in well-defined cell lines we could confirm that BTK is an upstream regulator of MALT1 activity in CD79 mutant, but not in CARMA1 mutant DLBCL cells. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.